Halozyme Therapeutics — Jan 8, 2025 release

For the full year 2025, the Company expects: • Total revenue of $1,150 million to $1,225 million, representing growth of 16% to 23% over projected 2024 total revenue, primarily driven by increases in royalty revenue and product sales from XYOSTED ® . • Revenue from royalties of $725 million to $750 million, representing growth of 30% to 35% over 2024. • Adjusted EBITDA of $755 million to $805 million, representing growth of 24% to 32% over 2024. • Non-GAAP diluted earnings per share of $4.95 to $5.35, representing growth of 21% to 30% over 2024. The Company’s earnings per share guidance does not consider the impact of potential future share repurchases. Table 2. 2025 Financial Guidance   Previous Guidance Range New Guidance Range Expected YoY Growth 1 Total Revenue $1,095 to $1,170 million $1,150 to $1,225 million 16% to 23% Royalty Revenue $650 to $675 million $725 to $750 million 30% to 35% Adjusted EBITDA $710 to $760 million $755 to $805 million 24% to 32% Non-GAAP Diluted EPS $4.45 to $4.85 $4.95 to $5.35 21% to 30% Footnote: 1 Growth rates calculated from 2024 midpoint to low end of 2025 range and high-end of 2025 range. Website and Conference Call Halozyme will host an Investor Conference Call today, Wednesday, January 8 at 5:30am PT/8:30am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance. Pre-regis